New combo therapy tested for advanced liver cancer
NCT ID NCT07362264
First seen Jan 25, 2026 · Last updated May 22, 2026 · Updated 16 times
Summary
This early-stage study tests a new drug called SH006, given in combination with other treatments, for people with advanced solid tumors (including liver cancer) who have not responded to standard therapy. The main goals are to check safety, find the best dose, and see if the drug helps shrink tumors. About 50 adults aged 18 to 75 are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Nanjing Tianyinshan Hospital
Nanjing, Jiangsu, China
Conditions
Explore the condition pages connected to this study.